GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update
Cash and cash equivalents totaled €113.8 million as of June 30, 2026; expected to fund the Company beyond the end of 2028
€21.1 million in revenues as of June 30, 2026, including €21.0 million in royalties generated under the Ipsen agreement
PBC: Ipsen doubled its peak annual global sales target for Iqirvo® in PBC to €1 billion, underscoring the value creation potential of GENFIT’s licensing agreement
MASH: Medicare coverage secured in August 2026 in the United States for NASHnext®, the Labcorp-commercialized test based on GENFIT’s NIS™ technology; estimated U.S. peak sales of products based on GENFIT’s NIS™ technology could exceed $1.5 billion by 2033 (IQVIA)
ACLF: Clinical-stage pipeline re-focused on the planned initiation of two Phase 2 clinical trials, of nangibotide and nitazoxanide, before year-end
CCA: Continued advancement of GNS561 in combination therapy, including expansion of the Phase 1b study into additional cohorts following encouraging preliminary data; preparation for a Phase 2 trial expected to commence before year-end
About GENFIT
GENFIT, a BCorp™ certified company since 2025, is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades
Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA).
Its R&D portfolio, covering several stages of development, ensures a constant news flow.
Our Therapeutic Areas
Our R&D pipeline covers 3 programs at clinical stage:
2 assets in Acute-on-Chronic Liver Failure (ACLF)
1 asset in Oncology
Several programmes are being developed at research stage targeting ACLF and oncology.
Beyond therapeutics, GENFIT’s pipeline also includes a diagnostic franchise focused on NASH/MASH1 and ammonia.
Our Success in PBC
In June 2023, GENFIT and Ipsen announced positive topline 52-week data from the pivotal Phase 3 trial ELATIVE® evaluating elafibranor in Primary Biliary Cholangitis (PBC). This asset was discovered and successfully developed by GENFIT.
In 2024, Iqirvo® (elafibranor) received Accelerated Approval by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for the treatment of Primary Biliary Cholangitis (PBC).
Iqirvo® is now marketed in several countries.[1]
[1] Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®
Our Documentation
Latest Press Releases
Our CSR Commitment
We believe that Corporate Social Responsibility (CSR) is a key driver for success. Our positioning in the healthcare sector, at the service of patients, is a central element of our societal commitment, which we complement with proactive social and environmental policies and initiativesdeveloped and carried out by our teams. Our actions are coordinated through a system of corporate governance that meets demanding criteria in terms of ethics, responsibility and fairness.
Our videos
1 At EASL Congress in June 2023 it was announced that nonalcoholic steatohepatitis (NASH) would now be referred to as Metabolic dysfunction-associated steatohepatitis (MASH). Nonalcoholic fatty liver disease (NAFLD) will now be referred to as metabolic dysfunction-associated steatotic liver disease (MASLD). GENFIT is progressively transitioning its documentation over to this new nomenclature and both NASH and MASH terms may appear in our documents during this period
2 GENFIT Communique de presse – 30 juin 2023 : Ipsen et GENFIT annoncent les résultats positifs de l’essai de Phase III ELATIVE® évaluant elafibranor chez des patients atteints de cholangite biliaire primitive, une maladie cholestatique rare du foie